New book by Larry Connors Click here Improve your trading - See how
FinancialBusinessNews is an affiliate of Stock Profiler.US, LLC. Stock Profiler invites investors to chat about Infinity Medical Group Inc. (PINKSHEETS: IMGR | Quote | Chart | News | PowerRating) and Delcath Systems, Inc. (NASDAQ: DCTH | Quote | Chart | News | PowerRating) on their new website, which has been upgraded with FREE Investor Tools, Live Chats, and much more! Sign up now at www.stockprofiler.us. Companies who want to broadcast their message are encouraged to contact us at (603) 424-4420.
-------------------------------------------
Infinity Medical Group Inc. (PINKSHEETS: IMGR | Quote | Chart | News | PowerRating) closed at $0.23 Wednesday, trading 369,591 shares.
Company News- July 22, 2008: Infinity Medical Group Inc. Introduces the Titan Procedure for Its Laser and Skin Care Clinics
Infinity Medical Group Inc. (PINKSHEETS: IMGR), a specialty healthcare development company focusing on the building, finance and management of cosmetic medical laser and dental implant clinics that offer elective medical and dental procedures, announced Tuesday that through its partner Rejuvena Medspa, Rejuvena Skin and Laser Centers are proud to offer the Titan procedure. The Titan Laser is a skin tightening procedure that many are calling a non surgical facelift. The Titan procedure is the first non-surgical light-based system approved by the FDA and Health Canada for the safe treatment of lax and/or redundant skin by deep dermal heating. Studies show the number of Americans over 55 will grow by 60% in the next 20 years and their buying power will exceed $2 trillion by 2007.
Americans spent just under $9.4 billion on cosmetic medical procedures in 2003. In 2004, American consumers spent $44.6 billion on anti-aging products and services, and the total anti-aging market is projected to reach $72 billion by 2009 (Business Communications Co., Inc., February 2005).
Infinity Medical Group Inc. is a specialty healthcare development company whose primary focus is in servicing the cosmetic medical laser and dental implant fields. Infinity Medical Group provides turnkey support for both medical and dental professionals and aids in their professional development through the emerging fields of cosmetic medical lasers and dental implants. Infinity differentiates itself by offering "a hands-on approach to finance, building, systemization, branding, containment, training and development of its group of clinics." "We are excited to announce that the Titan procedure is available directly through Rejuvena. With an estimated 2,000 Americans turning 50 every day (1 every 8 seconds) for the next 20 years we expect demand to be strong for the Titan procedure for many years to come. Clients have been successfully treated on many areas of the body including the face, chin, neck and stomach to remove post pregnancy stretch marks. Unlike other skin firming treatments, the non-invasive Titan Procedure is painless, requires no downtime and can be used on all skin types." (Stefan Kim CEO - Infinity Medical Group)
About Infinity Medical Group Inc.
Infinity Medical Group Inc. is a specialty healthcare development company focusing on the building, finance and management of cosmetic medical laser and dental implant clinics offering elective procedures.
-------------------------------------------
Delcath Systems, Inc. (NASDAQ: DCTH | Quote | Chart | News | PowerRating) closed at $2.02 Wednesday, trading 23,100 shares.
Company News- July 24, 2008: Delcath Expands Phase III Trial for Metastatic Melanoma to Florida
Delcath Systems, Inc. (NASDAQ: DCTH | Quote | Chart | News | PowerRating) announced earlier today that Moffitt Cancer Center ("Moffitt"), a National Cancer Institute Comprehensive Cancer Center, has joined Delcath's Phase III clinical trial for the treatment of inoperable metastatic melanoma in the liver using the Company's Percutaneous Hepatic Perfusion (PHP) System for the isolated, high dose delivery of the anti-cancer agent melphalan. Moffitt is the seventh center in this multi-center trial using the Delcath System.
Delcath and Moffitt have entered into a clinical research agreement to conduct the Phase III National Cancer Institute (NCI) led study. Jonathan S. Zager, MD, Assistant Professor of Surgery in the Department of Oncologic Sciences and a member of the Division of Cutaneous Oncology at Moffitt will serve as the Principal Investigator of the study. On joining this study, Dr. Zager commented, "This is a tremendous opportunity for Moffitt and our patients to be able to enroll in this trial. Metastatic melanoma is a devastating disease, providing limited treatment options and resistant against most therapies. This trial provides hope and promise to patients suffering from this disease and we look forward to being able to assist in the enrollment process and bettering our patients' prognoses." Commenting on Moffitt joining this trial, Richard L. Taney, President and CEO of Delcath, stated, "Our expansion of this trial continues and we are very excited to be able to enroll patients at Moffitt under the leadership of Dr. Zager, who brings broad experience in melanoma and clinical research to this study. By working with leading melanoma physicians and centers, such as Dr. Zager and Moffitt, we are increasing the availability of this treatment option to more geographic regions and patients. We will continue our efforts to broaden the reach of this trial through the addition of recognized cancer centers, make this treatment option available to as many patients as possible, and to reach our goal of completing trial enrollment in 2009." The Phase III Study The Phase III study is designed to test Delcath's proprietary PHP System for the regional delivery of melphalan to the liver to treat patients with metastatic ocular and cutaneous melanoma who have unresectable tumors in the liver. The Delcath System is designed to deliver significantly higher doses of anti-cancer drugs to a patient's liver while preventing entry of the drugs to the rest of the patient's circulation. This isolation limits toxicities that result from systemic chemotherapy treatments.
Patients in the Phase III trial initially are randomized into one of two treatment arms, including immediate treatment with melphalan via the Delcath System or treatment with best alternative care. The study is designed to evaluate the duration of tumor response in each of the two study arms. Following guidelines established by U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA), when disease progresses in patients enrolled in the best alternative care arm of the trial, they are permitted to "cross over" and receive treatment with the Delcath System. The Phase III study, which recently exceeded 33% enrollment, is expected to be completed in 2009, leading to an application to the US Food and Drug Administration (FDA) for commercial approval of the PHP System.
About H. Lee Moffitt Cancer Center & Research Institute
Located in Tampa, Florida, Moffitt Cancer Center is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in U.S. News & World Report as one of "America's Best Hospitals" for cancer, as well as for ear, nose and throat. Moffitt's sole mission is to contribute to the prevention and cure of cancer.
About Delcath Systems, Inc.
Delcath Systems is a developmental stage company testing its percutaneous perfusion technology for the isolated delivery of high doses of therapeutic and chemotherapeutic agents. The Delcath System is currently being tested with the drug melphalan in Phase III and Phase II clinical trials. The Company's intellectual property portfolio currently consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.
-------------------------------------------
The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. FinancialBusinessNews.US has not been compensated for services rendered; FinancialBusinessNews.US is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers, go to http://www.financialbusinessnews.us/ (disclaimers).
CONTACT: FinancialBusinessNews.US e-mail: info@http://www.financialbusinessnews.us WWW: http://www.financialbusinessnews.us/
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
